254 related articles for article (PubMed ID: 28141684)
21. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
22. Radioiodine as an adjuvant therapy and its role in follow-up of differentiated thyroid cancer.
Padma S; Sundaram PS
J Cancer Res Ther; 2016; 12(3):1109-1113. PubMed ID: 28054519
[TBL] [Abstract][Full Text] [Related]
23. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
24. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
de la Fouchardière C
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
[TBL] [Abstract][Full Text] [Related]
25. New perspectives on the treatment of differentiated thyroid cancer.
Coelho SM; Carvalho DP; Vaisman M
Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):612-24. PubMed ID: 17684624
[TBL] [Abstract][Full Text] [Related]
26. Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond.
Bulotta S; Celano M; Costante G; Russo D
Curr Opin Oncol; 2020 Jan; 32(1):13-19. PubMed ID: 31599772
[TBL] [Abstract][Full Text] [Related]
27. Standard and emerging therapies for metastatic differentiated thyroid cancer.
O'Neill CJ; Oucharek J; Learoyd D; Sidhu SB
Oncologist; 2010; 15(2):146-56. PubMed ID: 20142332
[TBL] [Abstract][Full Text] [Related]
28. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
Kojic KL; Kojic SL; Wiseman SM
Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
[TBL] [Abstract][Full Text] [Related]
29. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
[TBL] [Abstract][Full Text] [Related]
30. Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.
Werner RA; Lückerath K; Schmid JS; Higuchi T; Kreissl MC; Grelle I; Reiners C; Buck AK; Lapa C
Sci Rep; 2016 Jun; 6():28081. PubMed ID: 27306607
[TBL] [Abstract][Full Text] [Related]
31. New Insights in Thyroid Cancer and p53 Family Proteins.
Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
[TBL] [Abstract][Full Text] [Related]
32. Radioiodine Refractory Differentiated Thyroid Cancer.
Chan WWL; Chan S; Kwong DLW
Methods Mol Biol; 2022; 2534():243-257. PubMed ID: 35670980
[TBL] [Abstract][Full Text] [Related]
33. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
Bulotta S; Celano M; Costante G; Russo D
Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
[TBL] [Abstract][Full Text] [Related]
34. Update on recent developments in the therapy of differentiated thyroid cancer.
Middendorp M; Grünwald F
Semin Nucl Med; 2010 Mar; 40(2):145-52. PubMed ID: 20113682
[TBL] [Abstract][Full Text] [Related]
35. Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer.
Kirtane K; Roth MY
Curr Treat Options Oncol; 2020 Feb; 21(3):18. PubMed ID: 32048061
[TBL] [Abstract][Full Text] [Related]
36. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.
Busaidy NL; Cabanillas ME
J Thyroid Res; 2012; 2012():618985. PubMed ID: 22530159
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib in the treatment of thyroid cancer.
Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
[TBL] [Abstract][Full Text] [Related]
38. New directions in the systemic treatment of metastatic thyroid cancer.
Higgins MJ; Forastiere A; Marur S
Oncology (Williston Park); 2009 Aug; 23(9):768-75. PubMed ID: 19777762
[TBL] [Abstract][Full Text] [Related]
39. The role of radioactive iodine in the treatment of well-differentiated thyroid cancer.
Weigel RJ; McDougall IR
Surg Oncol Clin N Am; 2006 Jul; 15(3):625-38. PubMed ID: 16882501
[TBL] [Abstract][Full Text] [Related]
40. Radioactive iodine therapy.
Lee SL
Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):420-8. PubMed ID: 22914564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
